share_log

Atara Biotherapeutics (NASDAQ:ATRA) Research Coverage Started at EF Hutton Acquisition Co. I

Atara Biotherapeutics (NASDAQ:ATRA) Research Coverage Started at EF Hutton Acquisition Co. I

Atara Biotherapeutics（纳斯达克股票代码：ATRA）的研究报道始于 EF Hutton 收购公司我
kopsource ·  2023/01/09 02:21

EF Hutton Acquisition Co. I assumed coverage on shares of Atara Biotherapeutics (NASDAQ:ATRA – Get Rating) in a report issued on Thursday, Benzinga reports. The brokerage issued a buy rating and a $25.00 target price on the biotechnology company's stock.

据Benzinga报道，我在周四发布的一份报告中假设了Atara BioTreateutics(纳斯达克：ATRA-GET Rating)的股票。该经纪公司对这家生物技术公司的股票发布了买入评级和25.00美元的目标价。

Separately, StockNews.com assumed coverage on Atara Biotherapeutics in a research report on Wednesday, October 12th. They issued a hold rating for the company. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, Atara Biotherapeutics currently has an average rating of Hold and a consensus price target of $19.50.

另外，StockNews.com在10月12日星期三的一份研究报告中对Atara BioTreateutics进行了报道。他们对该公司发布了持有评级。两名分析师对该股的评级为卖出，三名分析师给出了持有评级，三名分析师给出了该公司的买入评级。根据MarketBeat的数据，Atara BioTreateutics目前的平均评级为持有，共识目标价为19.50美元。

Get
到达
Atara Biotherapeutics
Atara生物治疗学
alerts:
警报：

Atara Biotherapeutics Stock Performance

Atara BioTreatetics股票表现

Shares of NASDAQ:ATRA opened at $3.50 on Thursday. Atara Biotherapeutics has a fifty-two week low of $2.83 and a fifty-two week high of $16.44. The business has a 50-day simple moving average of $4.08 and a two-hundred day simple moving average of $4.44. The firm has a market cap of $332.08 million, a price-to-earnings ratio of -1.42 and a beta of 1.08.

纳斯达克：ATRA周四开盘报3.5美元。Atara BioTreateutics的股价为2.83美元，为52周低点，52周高点为16.44美元。该业务的50日简单移动均线切入位在4.08美元，200日简单移动均线切入位在4.44美元。该公司市值为3.3208亿美元，市盈率为-1.42，贝塔系数为1.08。

Insider Buying and Selling at Atara Biotherapeutics

Atara BioTreatetics的内幕买卖

In other Atara Biotherapeutics news, CFO Utpal Koppikar sold 6,255 shares of the business's stock in a transaction dated Wednesday, November 16th. The stock was sold at an average price of $4.49, for a total transaction of $28,084.95. Following the completion of the sale, the chief financial officer now directly owns 191,334 shares in the company, valued at approximately $859,089.66. The transaction was disclosed in a filing with the SEC, which is available at
在Atara BioTreateutics的其他消息中，首席财务官Utpal Koppikar在11月16日星期三的交易中出售了6255股该公司的股票。该股以4.49美元的平均价格出售，总成交金额为28084.95美元。出售完成后，首席财务官现在直接拥有该公司191,334股，价值约859,089.66美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可在
the SEC website
美国证券交易委员会网站
. In other Atara Biotherapeutics news, CEO Pascal Touchon sold 15,591 shares of the business's stock in a transaction dated Wednesday, November 16th. The stock was sold at an average price of $4.49, for a total transaction of $70,003.59. Following the completion of the sale, the chief executive officer now directly owns 441,696 shares in the company, valued at approximately $1,983,215.04. The transaction was disclosed in a filing with the SEC, which is available at
。在Atara BioTreateutics的其他消息中，首席执行官Pascal Touchon在11月16日星期三的交易中出售了15,591股Atara BioTreateutics股票。该股以4.49美元的平均价格出售，总成交金额为70,003.59美元。出售完成后，行政总裁现直接持有该公司441,696股股份，价值约1,983,215.04美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可在
the SEC website
美国证券交易委员会网站
. Also, CFO Utpal Koppikar sold 6,255 shares of the business's stock in a transaction that occurred on Wednesday, November 16th. The shares were sold at an average price of $4.49, for a total value of $28,084.95. Following the transaction, the chief financial officer now owns 191,334 shares of the company's stock, valued at $859,089.66. The disclosure for this sale can be found
。此外，首席财务官Utpal Koppikar在11月16日星期三的一笔交易中出售了6255股该公司的股票。这些股票的平均价格为4.49美元，总价值为28,084.95美元。交易完成后，这位首席财务官现在拥有191,334股公司股票，价值859,089.66美元。关于这次销售的披露可以找到
here
这里
. Insiders sold a total of 29,800 shares of company stock worth $133,802 in the last three months. 4.00% of the stock is currently owned by company insiders.
。在过去的三个月里，内部人士总共出售了29,800股公司股票，价值133,802美元。4.00%的股份目前由公司内部人士持有。

Institutional Inflows and Outflows

机构资金流入和流出

A number of hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp grew its stake in shares of Atara Biotherapeutics by 117.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 642,158 shares of the biotechnology company's stock valued at $2,427,000 after acquiring an additional 347,261 shares during the period. Balyasny Asset Management LLC grew its stake in shares of Atara Biotherapeutics by 213.3% during the 3rd quarter. Balyasny Asset Management LLC now owns 58,472 shares of the biotechnology company's stock valued at $221,000 after acquiring an additional 39,806 shares during the period. BNP Paribas Arbitrage SNC grew its stake in shares of Atara Biotherapeutics by 637.5% during the 3rd quarter. BNP Paribas Arbitrage SNC now owns 198,267 shares of the biotechnology company's stock valued at $749,000 after acquiring an additional 171,382 shares during the period. Alliancebernstein L.P. grew its stake in shares of Atara Biotherapeutics by 43.4% during the 3rd quarter. Alliancebernstein L.P. now owns 107,040 shares of the biotechnology company's stock valued at $405,000 after acquiring an additional 32,400 shares during the period. Finally, State Street Corp grew its stake in shares of Atara Biotherapeutics by 30.1% during the 3rd quarter. State Street Corp now owns 8,097,353 shares of the biotechnology company's stock valued at $30,608,000 after acquiring an additional 1,875,667 shares during the period.

一些对冲基金最近改变了他们在该股的头寸。纽约梅隆银行(Bank Of New York Mellon Corp)在第三季度增持了Atara BioTreateutics股票117.8%。纽约梅隆银行(Bank Of New York Mellon Corp)目前持有这家生物技术公司642,158股票，价值2,427,000美元，在此期间又购买了347,261股票。Balyasny Asset Management LLC在第三季度将其在Atara BioTreateutics的股份增加了213.3%。Balyasny Asset Management LLC在此期间额外收购了39,806股，现在拥有58,472股这家生物技术公司的股票，价值221,000美元。法国巴黎银行套利SNC在第三季度将其在Atara BioTreateutics的股份增加了637.5%。法国巴黎银行套利SNC现在拥有这家生物技术公司198,267股股票，价值74.9万美元，在此期间又购买了171,382股。第三季度，联合伯恩斯坦公司在Atara BioTreateutics的持股增加了43.4%。在此期间，联合伯恩斯坦公司又购入了32,400股，现在拥有107,040股这家生物技术公司的股票，价值40.5万美元。最后，道富集团在第三季度增持了Atara BioTreateutics的股份30.1%。道富集团目前持有这家生物技术公司8,097,353股股票，价值30,608,000美元，在此期间又收购了1,875,667股。

Atara Biotherapeutics Company Profile

Atara生物疗法公司简介

(Get Rating)

(获取评级)

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma.

Atara BioTreateutics，Inc.是一家现成的T细胞免疫治疗公司，在美国开发癌症、自身免疫和病毒疾病患者的治疗方法。该公司正在开发Tabelecleucel，这是一种T细胞免疫疗法，处于第三阶段临床试验，用于治疗EB病毒(EBV)驱动的移植后淋巴增生性疾病，以及血液和实体肿瘤，包括鼻咽癌。

Recommended Stories

推荐故事

  • Get a free copy of the StockNews.com research report on Atara Biotherapeutics (ATRA)
  • Will LI Auto Be the Least Hated Chinese EV Stock in 2023?
  • Which Streaming Service Stock is Best in 2023?
  • Here's Why Snap Stock Can Double in 2023
  • MarketBeat: Week in Review 01/02-01/06
  • Why is the CrowdStrike Stock Price Struggling?
  • 免费获取StockNews.com关于Atara生物疗法(ATRA)的研究报告
  • 理想汽车会成为2023年最不招人恨的中国电动汽车股吗？
  • 哪种流媒体服务股票是2023年最好的？
  • 以下是Snap股票在2023年翻一番的原因
  • MarketBeat：回顾中的一周01/02-01/06
  • 为什么CrowdStrike的股价举步维艰？

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

获得Atara生物疗法日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Atara BioTreateutics和相关公司的最新新闻和分析师评级的每日简要摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发